Xeljanz
E474935
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Xeljanz canonical | 1 |
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
Janus kinase inhibitor
ⓘ
immunosuppressive agent ⓘ pharmaceutical drug ⓘ small molecule drug ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| belongsToTherapeuticClass |
disease-modifying antirheumatic drugs
ⓘ
targeted synthetic DMARDs ⓘ |
| contraindicatedIn |
hypersensitivity to tofacitinib
ⓘ
severe hepatic impairment ⓘ |
| developedBy | Pfizer NERFINISHED ⓘ |
| hasActiveIngredient | tofacitinib ⓘ |
| hasATCCode | L04AA29 ⓘ |
| hasBlackBoxWarning |
increased risk of mortality
ⓘ
malignancy and thrombosis ⓘ risk of serious infections ⓘ |
| hasBrandOwner | Pfizer NERFINISHED ⓘ |
| hasCommonAdverseEffect |
diarrhea
ⓘ
headache ⓘ nasopharyngitis ⓘ upper respiratory tract infection ⓘ |
| hasDosageForm |
extended-release tablet
ⓘ
oral tablet ⓘ |
| hasInternationalNonproprietaryName | tofacitinib NERFINISHED ⓘ |
| hasMechanismOfAction | Janus kinase (JAK) pathway inhibition ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSeriousAdverseEffect |
major adverse cardiovascular events
ⓘ
malignancy ⓘ serious infections ⓘ thrombosis ⓘ |
| indicatedFor |
active ankylosing spondylitis
ⓘ
active polyarticular course juvenile idiopathic arthritis ⓘ active psoriatic arthritis ⓘ moderate to severe rheumatoid arthritis ⓘ moderately to severely active ulcerative colitis ⓘ |
| isAdministeredWith | or without food ⓘ |
| regulates | cytokine signaling involved in immune response ⓘ |
| requiresMonitoringOf |
hemoglobin
ⓘ
lipid levels ⓘ liver enzymes ⓘ lymphocyte counts ⓘ neutrophil counts ⓘ |
| targets |
Janus kinase 1
NERFINISHED
ⓘ
Janus kinase 3 ⓘ |
| usedFor |
ankylosing spondylitis
ⓘ
polyarticular course juvenile idiopathic arthritis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.